Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Zhaoke Signs $130 Million Deal for Two Eyedrop Near-Vision Treatments

publication date: May 11, 2022

Zhaoke Ophthalmology of Hong Kong acquired China/Southeast Asia rights for two eyedrop candidates designed to improve near vision from Seattle’s Visus Therapeutics in a $130 million deal. Brimochol PF and Carbachol PF are investigational, once-daily therapeutics that reduce the size of the pupil, resulting in a “pinhole effect,” allowing only centrally focused light rays to enter the eye. This sharpens near and intermediate images. ZKO will make a $15 million upfront payment and up to $115 million in milestones, plus royalties. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China